Miller; Steven T.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Miller; Steven T..The latest application filed is for "rnai-mediated inhibition of tumor necrosis factor alpha-related conditions".

Company Profile

1.25.33

Miller; Steven T. - Arlington TX
Miller; Steven T. - Fort Wayne IN
Miller; Steven T. - Wilmington DE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
RNAi-Mediated Inhibition of Tumor Necrosis Factor Alpha-Related Conditions App 20190032061 - Yanni; John M. ; et al.	2019-01-31
RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of CAMP-related ocular disorders Grant 9,765,340 - Yanni , et al. September 19, 2	2017-09-19
RNAi-mediated inhibition of histamine receptor H1-related conditions Grant 9,745,585 - Yanni , et al. August 29, 2	2017-08-29
RNAi-Mediated Inhibition of Phosphodiesterase Type 4 for Treatment of CAMP-Related Ocular Disorders App 20170051291 - Yanni; John M. ; et al.	2017-02-23
RNAi-Mediated Inhibition of Tumor Necrosis Factor Alpha-Related Conditions App 20160369283 - Yanni; John M. ; et al.	2016-12-22
RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders Grant 9,453,220 - Yanni , et al. September 27, 2	2016-09-27
RNAi-mediated inhibition of tumor necrosis factor .alpha.-related conditions Grant 9,447,419 - Yanni , et al. September 20, 2	2016-09-20
RNAi-MEDIATED INHIBITION OF SPLEEN TYROSINE KINASE-RELATED INFLAMMATORY CONDITIONS App 20160257963 - Yanni; John M. ; et al.	2016-09-08
RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions Grant 9,371,529 - Yanni , et al. June 21, 2	2016-06-21
RNAi-MEDIATED INHIBITION OF HISTAMINE RECEPTOR H1-RELATED CONDITIONS App 20160053270 - Yanni; John M. ; et al.	2016-02-25
RNAi-mediated inhibition of histamine receptor H1-related conditions Grant 9,206,428 - Yanni , et al. December 8, 2	2015-12-08
RNAi-MEDIATED INHIBITION OF SPLEEN TYROSINE KINASE-RELATED INFLAMMATORY CONDITIONS App 20140357695 - Yanni; John M. ; et al.	2014-12-04
RNAi-MEDIATED INHIBITION OF TUMOR NECROSIS FACTOR ALPHA-RELATED CONDITIONS App 20140357694 - Yanni; John M. ; et al.	2014-12-04
RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions Grant 8,865,671 - Yanni , et al. October 21, 2	2014-10-21
RNAi-MEDIATED INHIBITION OF PHOSPHODIESTERASE TYPE 4 FOR TREATMENT OF cAMP-RELATED OCULAR DISORDERS App 20140171487 - Yanni; John M. ; et al.	2014-06-19
RNAi-Mediated Inhibition of Histamine Receptor H1-Related Conditions App 20140088172 - Yanni; John M. ; et al.	2014-03-27
RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders Grant 8,673,873 - Yanni , et al. March 18, 2	2014-03-18
RNAi-mediated inhibition of histamine receptor H1-related conditions Grant 8,618,278 - Yanni , et al. December 31, 2	2013-12-31
RNAi-MEDIATED INHIBITION OF TUMOR NECROSIS FACTOR ALPHA-RELATED CONDITIONS App 20130338213 - Yanni; John M. ; et al.	2013-12-19
RNAi-mediated inhibition of tumor necrosis factor .alpha.-related conditions Grant 8,541,389 - Yanni , et al. September 24, 2	2013-09-24
RNAi-Mediated Inhibition of Histamine Receptor H1-Related Conditions App 20120264809 - Yanni; John M. ; et al.	2012-10-18
RNAi-mediated inhibition of histamine receptor H1-related conditions Grant 8,222,227 - Yanni , et al. July 17, 2	2012-07-17
RNAi-Mediated Inhibition of Spleen Tyrosine Kinase-Related Inflammatory Conditions App 20110288157 - Yanni; John M. ; et al.	2011-11-24
RNAi-Mediated Inhibition of Histamine Receptor H1-Related Conditions App 20110269822 - Yanni; John M. ; et al.	2011-11-03
RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions Grant 8,048,863 - Yanni , et al. November 1, 2	2011-11-01
RNAi-mediated inhibition of histamine receptor H1-related conditions Grant 8,017,592 - Yanni , et al. September 13, 2	2011-09-13
RNAi-MEDIATED INHIBITION OF TUMOR NECROSIS FACTOR ALPHA-RELATED CONDITIONS App 20110142767 - Yanni; John M. ; et al.	2011-06-16
3,6-substituted imidazol[1,2-b]pyridazine analogs for treating allergic and inflammatory diseases Grant 7,906,512 - Hellberg , et al. March 15, 2	2011-03-15
5-substituted 2-aminopyridine analogs for treating allergic and inflammatory diseases Grant 7,799,778 - Hellberg , et al. September 21, 2	2010-09-21
3,6-substituted Imidazol[1,2-b]pyridazine Analogs For Treating Allergic And Inflammatory Diseases App 20100168116 - Hellberg; Mark R. ; et al.	2010-07-01
RNAI-mediated inhibition of tumor necrosis factor .alpha.-related conditions Grant 7,732,421 - Yanni , et al. June 8, 2	2010-06-08
3,6-substituted imidazol[1,2-b]pyridazine analogs for treating allergic and inflammatory diseases Grant 7,713,975 - Hellberg , et al. May 11, 2	2010-05-11
RNAi-Mediated Inhibition of Spleen Tyrosine Kinase-Related Inflammatory Conditions App 20090324507 - Yanni; John M. ; et al.	2009-12-31
RNAi-Mediated Inhibition of Histamine Receptor H1-Related Conditions App 20090274631 - Yanni; John M. ; et al.	2009-11-05
Use Of A Combination Of Olopatadine And Cilomilast To Treat Non-infectious Rhinitis And Allergic Conjunctivitis App 20090182035 - Yanni; John M. ; et al.	2009-07-16
Use of an Inhibitor of TNFa Plus an Antihistamine to Treat Allergic Rhinitis and Allergic Conjunctivitis App 20080254029 - Yanni; John M. ; et al.	2008-10-16
Use Of Connective Tissue Mast Cell Stabilizers To Facilitate Ocular Surface Re-epithelization And Wound Repair App 20080139531 - Yanni; John M. ; et al.	2008-06-12
Use Of Oculosurface Selective Glucocorticoid In The Treatment Of Dry Eye App 20080096852 - YANNI; John M. ; et al.	2008-04-24
Rnai-mediated Inhibition Of Tumor Necrosis Factor Alpha-related Conditions App 20070281901 - Yanni; John M. ; et al.	2007-12-06
Treatment of dry eye restoring 15-lipoxygenase activity to ocular surface cells App 20060217325 - Yanni; John M. ; et al.	2006-09-28
Use of oculosurface selective glucocorticoid in the treatment of dry eye App 20060058277 - Yanni; John M. ; et al.	2006-03-16
Treatment of dry eye by restoring 15-lipoxygenase activity to ocular surface cells App 20040248794 - Yanni, John M. ; et al.	2004-12-09
Use of oculosurface selective glucocorticoid in the treatment of dry eye App 20040132704 - Yanni, John M. ; et al.	2004-07-08
Disulfide derivatives useful for treating allergic diseases App 20020193633 - Feng, Zixia ; et al.	2002-12-19
Disulfide derivatives useful for treating allergic diseases App 20020193634 - Feng, Zixia ; et al.	2002-12-19
Aniline disulfide derivatives for treating allergic diseases App 20020115658 - Hellberg, Mark R. ; et al.	2002-08-22
Use of hydroperoxyeicosatetraenoic acid derivatives following refractive surgery App 20020077358 - Yanni, John M. ; et al.	2002-06-20
Compositions containing a benzamide disulfide derivative for treating allergic diseases App 20020065281 - Miller, Steven T. ; et al.	2002-05-30
Disulfide derivatives useful for treating allergic diseases App 20020058709 - Feng, Zixia ; et al.	2002-05-16
Aniline disulfide derivatives for treating allergic diseases App 20020013311 - Hellberg, Mark R. ; et al.	2002-01-31
Compounds which inhibit human conjunctival mast cell degranulation for treating ocular allergic-type complications Grant 6,225,327 - Miller , et al. May 1, 2	2001-05-01
Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders Grant 5,696,166 - Yanni , et al. December 9, 1	1997-12-09
Pneumatic cylinder apparatus Grant 5,241,896 - Braun , et al. September 7, 1	1993-09-07
Catalytic abatement system Grant 4,054,418 - Miller , et al. October 18, 1	1977-10-18

Company Registrations

SEC

0000857299

MILLER STEVEN T

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.